CL2024002361A1 - Anticuerpos terapéuticos - Google Patents

Anticuerpos terapéuticos

Info

Publication number
CL2024002361A1
CL2024002361A1 CL2024002361A CL2024002361A CL2024002361A1 CL 2024002361 A1 CL2024002361 A1 CL 2024002361A1 CL 2024002361 A CL2024002361 A CL 2024002361A CL 2024002361 A CL2024002361 A CL 2024002361A CL 2024002361 A1 CL2024002361 A1 CL 2024002361A1
Authority
CL
Chile
Prior art keywords
therapeutic antibodies
antibodies
eczema
modulate
signal transduction
Prior art date
Application number
CL2024002361A
Other languages
English (en)
Spanish (es)
Inventor
Bandiera Roberto
Original Assignee
Petmedix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2209454.4A external-priority patent/GB202209454D0/en
Application filed by Petmedix Ltd filed Critical Petmedix Ltd
Publication of CL2024002361A1 publication Critical patent/CL2024002361A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024002361A 2022-02-09 2024-08-07 Anticuerpos terapéuticos CL2024002361A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB202201674 2022-02-09
GBGB2209454.4A GB202209454D0 (en) 2022-06-28 2022-06-28 Therapeutic antibodies

Publications (1)

Publication Number Publication Date
CL2024002361A1 true CL2024002361A1 (es) 2024-11-29

Family

ID=85283675

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002361A CL2024002361A1 (es) 2022-02-09 2024-08-07 Anticuerpos terapéuticos

Country Status (11)

Country Link
US (1) US20250340659A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476256A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506488A (cg-RX-API-DMAC7.html)
KR (1) KR20240139085A (cg-RX-API-DMAC7.html)
AU (1) AU2023219227A1 (cg-RX-API-DMAC7.html)
CA (1) CA3258958A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002361A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010901A2 (cg-RX-API-DMAC7.html)
IL (1) IL314314A (cg-RX-API-DMAC7.html)
MX (1) MX2024009898A (cg-RX-API-DMAC7.html)
WO (1) WO2023152486A1 (cg-RX-API-DMAC7.html)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
KR102119840B1 (ko) 2011-07-11 2020-06-09 아이크노스 사이언스 에스. 아. Ox40에 결합하는 항체 및 이들의 용도
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EA032389B1 (ru) * 2012-02-14 2019-05-31 Мериал, Инк. Рекомбинантные поксвирусные векторы, кодирующие и экспрессирующие гликопротеин g вируса бешенства и полипептид oxl, и вакцины, созданные на их основе, используемые в способе вакцинации животных против бешенства
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
GB2561352B (en) 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
JP7449234B2 (ja) 2018-03-16 2024-03-13 ゾエティス・サービシーズ・エルエルシー 獣医学使用のためのインターロイキン31モノクローナル抗体
GB2578867A (en) 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
GB202012331D0 (en) * 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies

Also Published As

Publication number Publication date
MX2024009898A (es) 2024-08-20
EP4476256A1 (en) 2024-12-18
JP2025506488A (ja) 2025-03-11
KR20240139085A (ko) 2024-09-20
IL314314A (en) 2024-09-01
WO2023152486A1 (en) 2023-08-17
CA3258958A1 (en) 2023-08-17
CO2024010901A2 (es) 2024-10-31
US20250340659A1 (en) 2025-11-06
AU2023219227A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
DOP2024000207A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
CO2021003036A2 (es) Compuestos de anillo fusionado
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
JOP20230123A1 (ar) تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
MX2022010229A (es) Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
JOP20230109A1 (ar) أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات
ECSP088613A (es) Moléculas de anticuerpo que tienen especificidad para la il-6 humana
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
CL2025000063A1 (es) Anticuerpos anti-abeta
CL2023003073A1 (es) Anticuerpos anti-cd20 y estructuras car-t
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
JOP20240132A1 (ar) أجسام مضادة لـ c3 وشظايا ارتباط بمولد الضد منها واستخداماتها لعلاج العين أو الأمراض العينية
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CO2024010901A2 (es) Anticuerpos terapéuticos
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
CL2025002201A1 (es) Métodos de tratamiento de trastornos neurológicos con anticuerpos anti-abeta
CL2022001684A1 (es) Anticuerpo con especificidad de unión para il-13 humana
BR112022013553A2 (pt) Composição farmacêutica, anticorpo, e, método para tratar uma doença
CO2022015105A2 (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas